Mary Kay Borgstrom - Comment

Document ID: FDA-2011-N-0802-0006
Document Type: Public Submission
Agency: Food And Drug Administration
Received Date: April 10 2012, at 12:00 AM Eastern Daylight Time
Date Posted: April 12 2012, at 12:00 AM Eastern Standard Time
Comment Start Date: November 17 2011, at 12:00 AM Eastern Standard Time
Comment Due Date: June 12 2012, at 11:59 PM Eastern Standard Time
Tracking Number: 80fec734
View Document:  View as format xml

View Comment

I stongly support the increase availability of Naloxone in the prevention of Opioid Overdose. Making naloxone availalble saves lives! I work as a nurse on a adult detox center at the University of Minnesota, Fairivew and we have noticed an alarming upward trend of 18 y o to 28 y o heroin addicts. Most started with abuse of narcotics then switched to heroin. Many are motivated to come to treatment because a friend overdosed and died. Recently I cared for a young male who came in because he himself nearly died of an overdose but a friend did rescue breathing and got him to an ER. Unfortunetly this friend overdosed the next day and died. We just had a high school student overdose on heroin and alcohol and died. As a mother and a nurse I request you make naloxone and needles available to the public. One idea would be to have public health and/ or pharmacy's distribute the medication/syringes after a person views an informational adminstartion/safety video on an i-pad. As a community in the Twin Cities we organized a multi -agencyOpioid coaltion to fight this horrific trend of young opioid abusers. Availability of Naxolone is one layer of a solution to this problem. Additonal prevention and public education measures are urgently needed for this nation wide epidemic. Thank you, Mary Kay Borgstrom RN Opioid Coalition Prevention Leader www.opioidcoalition.org

Related Comments

    View All
Total: 37
Rudolph Joseph Maier, MD - Comment
Public Submission    Posted: 02/28/2012     ID: FDA-2011-N-0802-0002

Jun 12,2012 11:59 PM ET
Pain Treatment Topics (Pain-Topics.org) - Comment
Public Submission    Posted: 04/12/2012     ID: FDA-2011-N-0802-0003

Jun 12,2012 11:59 PM ET
mark eisenberg - Comment
Public Submission    Posted: 04/12/2012     ID: FDA-2011-N-0802-0005

Jun 12,2012 11:59 PM ET
Mary Kay Borgstrom - Comment
Public Submission    Posted: 04/12/2012     ID: FDA-2011-N-0802-0006

Jun 12,2012 11:59 PM ET
Jeffrey Joseph Cece - Comment
Public Submission    Posted: 04/12/2012     ID: FDA-2011-N-0802-0007

Jun 12,2012 11:59 PM ET